



# Resource impact template

Resource impact

Published: 11 December 2025

[www.nice.org.uk](http://www.nice.org.uk)

NICE has produced a [resource impact template](#) that incorporates the following technology appraisal guidance for transthyretin amyloidosis with cardiomyopathy:

- [Tafamidis for treating transthyretin amyloidosis with cardiomyopathy](#) (2024) NICE technology appraisal guidance 984
- [Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy](#) (2025) NICE technology appraisal guidance 1115